VERVE THERAPEUTICS IN

5.8200

27-November-24 15:48:29

15 minutes delayed

Stocks

+0.5100

+9.60%

Today's range

5.3000 - 5.8400

ISIN

N/A

Source

NASDAQ

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

24 Mar 2022 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

23 Feb 2022 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

10 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer

29 Nov 2021 08:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results

10 Nov 2021 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates

09 Nov 2021 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

21 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.